EUACCBack to showcase
CAMINO SCIENCE

CAMINO SCIENCE

Grant-FundedCORDIS

in silico bio-evolutio - novel AI paradigm for molecular biology

Visit website
AI / ML · Digital Health
The success of phage therapies relies on correctly matching a therapeutic phage to bacterial strain. However calibration of therapy recipe may last for years. Presented solution enable to accelerate this by in silico simulations on AI platform for in vitro. It is able to find optimal phage that meets the phenotype imposed by the researcher, especially: -predict given phage effectiveness against a specific bacteria strain, -indicate mutations that increase phage effectiveness, -generate explanations for predictions. Currently, this process is performed by wet-lab employees (in vitro). Replacing it with an in silico process will reduce the number 90 out of 100 experiments, significantly accelerating the process and improving phage therapy quality. At the same time, it’s the basis for modern probiotics (for microbiome modulation). At the same time, it will enable dynamically generate personalized therapies for specific patients. It is a novel endeavor in the area of molecular biology.
EU Grants€1.7M
Open to funding

Team

AP

Asis Palazon

Founder

All-time revenue
MRRPrivate••••••
FounderAsis Palazon
Founded
🇵🇱Poland
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics

Startup insights

Business detailsB2B
AI / MLDigital Health
Tags:AI / MLDigital Health
Looking for:InvestmentPartnerships